Sagent Pharmaceuticals (SGNT) Tops Q4 EPS by 20c, Provides Outlook
Tweet Send to a Friend
Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) reported Q4 EPS of $0.00, $0.20 better than the analyst estimate of ($0.20). Revenue for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE